{
  "schemaVersion": 1,
  "id": "research-192",
  "slug": "192-what-a-placebo-controlled-rett-syndrome-trial-found-about-mecasermin",
  "title": "What a placebo-controlled Rett syndrome trial found about mecasermin",
  "catalogLabel": "IGF-1 Human",
  "productCollection": "https://heritagebiolabs.com/research-library/products/igf-1-human",
  "productHandles": [
    "igf-1-human-625"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/igf-1-human-625"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 294,
  "sourceYears": [
    2018,
    2026
  ],
  "paragraphs": [
    "Peptides are short amino-acid chains held together by peptide bonds. Some longer amino-acid chains influence how cells grow and communicate. Human insulin-like growth factor 1 (IGF-1) is a 70-residue hormone, and mecasermin is its recombinant pharmaceutical form. An older trial tested whether that medicine improved symptoms in children with Rett syndrome, a different question from treating growth failure. [1, 2]",
    "No recent primary trial of mecasermin for this specific question was identified. In the older study, 30 girls with classic Rett syndrome were randomly assigned to receive either mecasermin or placebo in the first study period and switched to the other condition in the second. An interval separated the periods. The trial was double-blind, so participants, caregivers and the research team were masked to assignment. The investigators assessed several behavioral and clinical measures and examined exploratory recordings of breathing, heart function and brain activity. [1]",
    "The trial did not find a statistically clear benefit across its principal comparisons. Some participants had deviations from the planned treatment exposure, which complicated interpretation. The investigators also reported adverse events during the study. In a crossover design, each participant can provide a comparison under both conditions. The interpretation still depends on the completeness of those observations and on whether changes from the first period could affect the second. [1]",
    "The study shows why a proposed role for a signaling molecule in the nervous system is a rationale for testing, while measurable symptom change remains a separate question. The approved U.S. label for mecasermin covers defined pediatric growth disorders. Rett syndrome was the condition investigated in this trial and does not appear in those approved indications. The study's outcome applies to the tested medicine and does not establish how other compounds in the IGF-1 pathway would perform. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "O'Leary HM et al. Placebo-controlled crossover assessment of mecasermin for the treatment of Rett syndrome. Annals of Clinical and Translational Neurology (publication 2018-01-31).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/29560377/"
    },
    {
      "number": 2,
      "citation": "Eton Pharmaceuticals, Inc. INCRELEX (mecasermin) injection, for subcutaneous use. DailyMed (label effective 2026-05-18).",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/192-what-a-placebo-controlled-rett-syndrome-trial-found-about-mecasermin",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/192-what-a-placebo-controlled-rett-syndrome-trial-found-about-mecasermin.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/192-what-a-placebo-controlled-rett-syndrome-trial-found-about-mecasermin.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 039 - IGF-1 Human and IGF-1 DES 1 3.docx",
    "sourceArticleNumber": 192,
    "contentSha256": "461498ef21bee3e07366906b37d9743770e94ec758044e33921c642f3df39141",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
